## Accepted Manuscript

Pharmacologic treatments for rosacea

Alison M Layton MB, ChB, FRCP

PII: S0738-081X(16)30277-2

DOI: doi: 10.1016/j.clindermatol.2016.10.016

Reference: CID 7114

To appear in: Clinics in Dermatology



Please cite this article as: Layton Alison M, Pharmacologic treatments for rosacea, *Clinics in Dermatology* (2016), doi: 10.1016/j.clindermatol.2016.10.016

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## CCEPTED MANUSCRIPT

Pharmacologic treatments for rosacea.

Author and affiliation: Alison M Layton, MB, ChB, FRCP

Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom; alison.layton@hdft.nhs.uk;

Corresponding author: Alison M Layton, MB, ChB, FRCP

Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom; alison.layton@hdft.nhs.uk; 00 441423 553740

Disclosures: Dr Layton, has served as a consultant for Steifel-GSK Inc, MEDA Inc, Galderma; Gillette and L'Oreal

### **ABSTRACT**

Rosacea represents a common and chronic inflammatory skin disorder. Clinical features include transient and permanent erythema, inflammatory papules and pustules, phymatous changes and ocular signs and symptoms (1). Rosacea is generally classified into four subtypes and one variant (2). Subtype 1: erythematotelangiectatic rosacea, includes clinical features of flushing and

### Download English Version:

# https://daneshyari.com/en/article/5645681

Download Persian Version:

https://daneshyari.com/article/5645681

<u>Daneshyari.com</u>